您好,欢迎来到试剂仪器网! [登录] [免费注册]
试剂仪器网
位置:首页 > 产品库 > Metoclopramide
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
Metoclopramide
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
Metoclopramide图片
CAS NO:364-62-5
包装与价格:
包装价格(元)
10mM (in 1mL DMSO)电议
100mg电议
500mg电议

产品介绍
Dopamine receptor antagonist
Cas No.364-62-5
别名胃复安
化学名4-amino-5-chloro-N-[2-(diethylamino)ethyl]-2-methoxybenzamide
Canonical SMILESCCN(CC)CCNC(=O)C1=CC(=C(C=C1OC)N)Cl
分子式C14H22ClN3O2
分子量299.8
溶解度≥ 14.99 mg/mL in DMSO, ≥ 24.6 mg/mL in EtOH with gentle warming
储存条件Store at 2-8℃, protect from light
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

Metoclopramide is a dopamine D2 antagonist that is used as an antiemetic.IC50 Value:Target: D2 ReceptorMetoclopramide is a dopamine receptor antagonist which has been used for treatment of a variety of gastrointestinal symptoms over the last thirty years. In various countries, metoclopramide is the antiemetic drug of choice in pregnant women. Findings provide reassurance regarding the safety of metoclopramide for the fetus when the drug is given to women to relieve nausea and vomiting during pregnancy. Evidence also supports its use for gastroparesis (poor stomach emptying) and gastroesophageal reflux disease. It appears to bind to dopamine D2 receptors where it is a receptor antagonist, and is also a mixed 5-HT3 receptor antagonist/ 5-HT4 receptor agonist.

References:
[1]. Navari RM, Nagy CK, Gray SE. The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer. 2013 Jan 12.
[2]. Gutiérrez-Hermosillo H, Díaz de León-González E, Beltrán Santiago D et al. Metoclopramide as a risk factor for postprandial hyperglycemia in type 2 diabetes. Nutr Hosp. 2012 Jul-Aug;27(4):1267-71.
[3]. Ilan Matok, Sc.Pharm., Rafael Gorodischer, et al. The Safety of Metoclopramide Use in the First Trimester of Pregnancy. N Engl J Med 2009; 360:2528-2535.
[4]. DN Bateman, C Kahn, K Mashiter, DS Davies. Pharmacokinetic and concentration-effect studies with intravenous metoclopramide. British Journal of Clinical Pharmacology.1978,6(5): 401-407